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Abstract
The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most altered in cancer, leading to a range of
cellular responses including enhanced proliferation, survival, and metabolism, and is thus an attractive target for
anticancer drug development. Stimulation of the PI3K pathway can be initiated by alterations at different levels of
the signaling cascade including growth factor receptor activation, as well as mutations in PIK3CA, PTEN, and AKT
genes frequently found in a broad range of cancers. Given its role in glucose metabolism, we investigated the
utility of [18F]fluorodeoxyglucose positron emission tomography ([18F]FDG PET) as a pharmacodynamic biomarker
of PI3K pathway–induced glucose metabolism. PTEN deletion in human colon carcinoma cells led to constitutive
AKT activation but did not confer a phenotype of increased cell proliferation or glucose metabolism advantage
in vivo relative to isogenic tumors derived from cells with a wild-type allele. This was not due to the activation
context, that is, phosphatase activity, per se because PIK3CA activation in xenografts derived from the same line-
age failed to increase glucose metabolism. Acute inhibition of PI3K activity by LY294002, and hence decreased
activated AKT expression, led to a significant reduction in tumor [18F]FDG uptake that could be explained at least in
part by decreased membrane glucose transporter 1 expression. The pharmacodynamic effect was again indepen-
dent of PTEN status. In conclusion, [18F]FDG PET is a promising pharmacodynamic biomarker of PI3K pathway
inhibition; however, its utility to detect glucose metabolism is not directly linked to the magnitude of activated
AKT protein expression.
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Introduction
The phosphoinositide 3-kinase (PI3K) signaling pathway is one of
the most altered in cancer, initiating direct downstream activation
of the serine-threonine kinase AKT, which is vital to the growth and
survival of cancer cells [1]. As a major downstream effector of receptor
tyrosine kinases and G protein–coupled receptors, PI3K transduces
signals from various growth factors and cytokines into intracellular
messages by converting phosphatidylinositol-4,5-biphosphate (PIP2)
to phosphatidylinositol-3,4,5-triphosphate (PIP3) at the membrane,
providing docking sites for signaling proteins containing pleckstrin ho-
mology domains, including 3-phosphoinositide–dependent kinase 1
and serine-threonine kinase AKT. While colocated at the membrane,
3-phosphoinositide–dependent kinase 1 phosphorylates and activates
AKT, which elicits a wide range of downstream signaling events. The
tumor suppressor PTEN (phosphatase and tensin homolog) is the
most important negative regulator of the PI3K signaling pathway by
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functionally antagonizing PI3K activity through its intrinsic lipid
phosphatase activity that converts PIP3 back to PIP2, therefore reduc-
ing the cellular pool of PIP3 [2]. Recent human cancer genome studies
have revealed that many components of the PI3K pathway, including
the PIK3CA gene coding for the p110 catalytic subunit of PI3K, and
the PTEN and AKT genes, are frequently mutated (germ line or somatic
mutations) in a broad range of human cancers. The PTEN gene was
initially identified as a tumor suppressor candidate in 1997 [3,4]. Nu-
merous mutations and/or deletions in the PTEN gene have been found
in human cancer cell lines and tumor tissues, indicating a strong asso-
ciation between loss of PTEN function and human cancer [2,5]. In ad-
dition, germ line mutations in the PTEN gene have been associated
with Cowden syndrome and related diseases in which patients experi-
ence a significantly increased risk of certain tumors, including breast
and thyroid carcinomas. Most PTEN-related studies have focused on
its tumor suppressor function, and an accumulating body of evidence
supports the notion that impaired PTEN function induces PIP3 accu-
mulation and subsequent AKT hyperactivation, leading to oncogenic
transformation of cells [6]. These findings, and the fact that PI3K
and other downstream kinases are amenable to pharmacological inter-
vention, make this pathway one of the most attractive therapeutic tar-
gets in cancer [7,8].
Given the large number of PI3K pathway therapeutics in develop-
ment, introduction of effective biomarkers that report on target in-
hibition or drug efficacy will benefit the various drug development
strategies. Although molecular pharmacological biomarkers of the
PI3K pathway based on immunohistochemical analyses of tissue bi-
opsy samples with phosphospecific antibodies of AKT are available,
these techniques have a number of limitations: routine immunohisto-
chemistry is largely qualitative, the location of the neoplastic tissue may
prevent the use of invasive procedures, and intratumoral molecular and
cellular heterogeneity may significantly confound analyses [9]. In this
context, the development of noninvasive imaging strategies to predict
and evaluate the activity of PI3K pathway inhibitors in patients would
be highly valuable. In the present study, we investigated the potential
utility of positron emission tomography (PET) imaging to characterize
PI3K signaling pathway activation status in tumor and response to
PI3K pathway targeting therapeutics.
The PI3K/AKT signaling pathway has notably been shown to
stimulate increased glucose uptake and metabolism in response to
growth factors through the increased transcription and plasma mem-
brane localization of the glucose transporter 1 (GLUT-1) [10], the
principal glucose transporter expressed in most cell types. The path-
way also regulates glycolysis by promoting hexokinase localization
to mitochondria and, consequently, glucose phosphorylation, as well
as expression of other glycolytic genes through activation of hypoxia-
inducible factor 1 [11–17]. This suggests that PET imaging with the
glucose analog [18F]fluorodeoxyglucose ([18F]FDG) could be useful
as a pharmacodynamic biomarker to probe biologic consequences of
the various oncogenic alterations leading to the PI3K pathway acti-
vation and, by extension, the response of tumors to PI3K pathway
targeting therapeutics.
In an effort to better understand the contribution of PTEN deletion
and subsequent AKT hyperactivation to glucose metabolism in vivo, we
investigated the dynamics of [18F]FDG uptake (and proliferation with
[18F]fluorothymidine ([18F]FLT)) in isogenic human colon carcinoma
cells that differed only in their PTEN status. We also investigated the
potential utility of [18F]FDG PET for monitoring PI3K inhibition, in
relation with the PTEN expression.
Materials and Methods
Cell Culture and Reagents
The isogenic human colon carcinoma set of cells HCT116 PTEN
WT/KO and PIK3CA WT/MUT were kindly provided by Dr Todd
Waldman and Pr Bert Vogelstein, respectively, and maintained as
previously described [18,19]. Insulin and LY294002 were purchased
from Sigma-Aldrich (Sigma-Aldrich Company Ltd, Dorset, United
Kingdom) and Calbiochem (Merck Chemicals Ltd, Nottingham,
United Kingdom), respectively.
Western Blot Analysis
HCT116 PTEN cells were cultured in six-well plates with com-
plete or serum-free growth medium (overnight incubation) and stim-
ulated with insulin at the indicated concentrations for 1 hour.
Protein samples were subsequently prepared by lysing cells in RIPA
buffer (Invitrogen Ltd, Paisley, United Kingdom) supplemented
with protease and phosphatase inhibitor cocktails (Sigma-Aldrich).
Tumor tissue samples were obtained as follows. Excised and snap-
frozen xenografts were homogenized in RIPA lysis buffer with the
PreCellys 24 homogenizer and CK14 beads-containing tubes (two cycles
of 25 sec/6500 rpm; Bertin Technologies, Montigny-Le-Bretonneux,
France). Equal amounts of protein (30 μg) were denaturated in sample
buffer, subjected to SDS–polyacrylamide gel electrophoresis on 4% to
12% gels (Invitrogen Ltd), and transferred to polyvinylidene fluoride
membranes (GE Healthcare Life Sciences, Buckinghamshire, United
Kingdom). The membranes were immunoblotted with specific primary
antibodies, horseradish peroxidase–conjugated secondary antibodies,
and visualized by enhanced chemiluminescence (GE Healthcare Life
Sciences). The following antibodies were used: anti–phospho-AKT
(Ser473) and anti–AKT rabbit polyclonal antibodies (Cell Signaling
Technology, Inc, Danvers, MA), a mouse monoclonal anti–PTEN
antibody (Cascade Bioscience, Winchester, MA), a mouse monoclonal
anti–α-tubulin antibody (Santa Cruz Biotechnology, Inc, Santa Cruz,
CA), and secondary goat antimouse and antirabbit horseradish per-
oxidase antibodies (Santa Cruz Biotechnology).
Proliferation Assay
Assessment of in vitro cell proliferation was performed using the
colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide MTT assay according to manufacturer’s instructions
(ATCC, Manassas, VA). Briefly, HCT116 PTEN cells were seeded
in triplicate in 96-well plates with complete or serum-free growth
medium in the absence or presence of PI3K inhibitor LY294002
(overnight incubation) and stimulated with insulin at the indicated
concentrations. Cell proliferation was quantified the next day by add-
ing 10 μl of MTT per well and recording the absorbance at 570 nm.
[18F]FLT and [18F]FDG Small-Animal PET Imaging
The in vivo experimental xenograft model was established by sub-
cutaneous injection of 1 × 106 HCT116 PTEN and PIK3CA iso-
genic cells on the flanks of 6- to 8-week-old female BALB/c nude
mice (Harlan, Wyton, United Kingdom), bilateral implants for each
pair of isogenic cells, that is, on the left and right flanks of the same
animal. All animal experiments were done by licensed investigators in
accordance with the UK Home Office Guidance on the Operation of
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the Animal (Scientific Procedures) Act 1986 (HMSO, London,
United Kingdom, 1990) and within guidelines set out by the UK
National Cancer Research Institute Committee on Welfare of Ani-
mals in Cancer Research [20]. When xenografts reached ∼100 mm3,
mice were injected twice with LY294002 (100 mg/kg intraperitone-
ally) or vehicle (10% dimethyl sulfoxide/phosphate-buffered saline)
at 3 hours 30 minutes before PET scanning. Imaging was performed
on a dedicated small-animal PET scanner (quad-HIDAC; Oxford
Positron Systems, Weston-on-the-Green, United Kingdom). Anes-
thetized animals were placed within a thermostatically controlled
bed and positioned prone within the scanner. The bed was calibrated
to provide a mouse rectal temperature of ∼37°C. A bolus injection
of [18F]FLT or [18F]FDG (∼3.7 MBq) was given intravenously
through the tail vein cannula, and scanning commenced. Dynamic
emission scans were acquired in list-mode format for 60 minutes.
The acquired data were then sorted into 0.5-mm sinogram bins
and 19 time frames (0.5 × 0.5 × 0.5-mm voxels; 4 × 15, 4 × 60,
and 11 × 300 seconds) for image reconstruction, which was done
by filtered back projection using a two-dimensional Hamming filter
(cutoff, 0.6). The image data sets obtained were transferred to a SUN
workstation (Ultra 10; SUN Microsystems, Santa Clara, CA) and
visualized using the Analyze software (version 6.0; Biomedical Imag-
ing Resource, Mayo Clinic, Rochester, MN). Cumulative images of
the dynamic data obtained 30 to 60 minutes (for tumor or liver) or
0 to 1 minutes (for heart) after radiotracer injection were used to
visualize radiotracer uptake and to define the regions of interest.
Count densities from at least five adjacent planes were averaged for
each region of interest at each of the 19 time points to obtain time-
versus-radioactivity curves (TACs). Tumor TACs were normalized to
those of heart or liver at each of the time points to obtain the normal-
ized uptake value (NUV). The NUV at 60 minutes after injection
(NUV60), the area-under-the-NUV curve (AUC) calculated as the in-
tegral of NUV from 0 to 60 minutes, and the fractional retention
of tracer (FRT), the radioactivity at 60 minutes relative to that at
2.5 minutes, were used for comparisons. FRT is a useful variable in that
it indicates the proportion of radiotracer delivered to the tumor that is
retained. It therefore normalizes tumor tracer uptake to delivery.
GLUT-1 Immunohistochemistry Assay
After PET imaging studies, tumor tissues were excised, fixed in
formalin, embedded in paraffin, sectioned (5-μm slices), and pro-
cessed for GLUT-1 fluorescent immunodetection using the anti–
GLUT-1 polyclonal antibody (Abcam, Cambridge, MA) coupled
with the Alexa Fluor 488 goat antirabbit (Invitrogen Ltd). The Pro-
Long Gold Antifade mounting solution (Invitrogen Ltd) containing
4′,6-diamidino-2-phenylindole was added to tissue sections before
mounting in coverslips, and images were captured using an Olympus
BX51 fluorescent microscope (Olympus Ltd, Southall, United Kingdom).
Statistical Analysis
Data were expressed as mean ± SEM, and the significance of com-
parison between two data sets was determined using Student’s t test
(GraphPad Prism, version 5.0a for Macintosh; GraphPad, San Diego,
Figure 1. Constitutive AKT activation and insulin-induced AKT hyper-
activation in HCT116 PTEN-deleted cells. (A) HCT116 PTEN WT and
KO cells were cultured overnight in the absence (0%) or presence
(10%) of fetal calf serum (FCS), and then stimulated with insulin
(1 or 100 nM) or corresponding vehicle for 1 hour. Protein lysates
were prepared, and immunoblots were performed with the indicated
primary antibodies. α-Tubulin was used as a loading control. (B)
Densitometry (optical density, OD) measurements of phospho-AKT/
total AKT ratio extracted from the protein immunoblots. Data repre-
sent the mean ± SEM of three to five independent experiments.
Figure 2. In vitro assessment of proliferation related to PTEN sta-
tus and LY294002 treatment. HCT116 PTENWT and KO cells were
cultured in the absence (0%) or presence (10%) of fetal calf serum
(FCS) and LY294002 (LY, 10 μM), and stimulated with insulin (ins,
1 or 100 nM) or corresponding vehicle overnight. Cell proliferation
was assessed after 24 hours. Data represent the mean ± SEM of
three to five independent experiments performed in triplicate.
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CA) and defined as significant (*.01 < P < .05), very significant
(**.001 < P < .01), and extremely significant (***P < .001).
Results
Effect of PTEN Deletion on AKT Status in Unstimulated and
Serum/Growth Factor–Stimulated Cancer Cells
We investigated the biologic impact of PTEN deletion on AKT
status using an isogenic set of human colon carcinoma cells that dif-
fer only in the presence or complete absence (through somatic cell
gene targeting) of endogenous wild-type PTEN expression (HCT116
PTENWT and HCT116 PTEN KO, respectively) [18]. As expected,
HCT116 PTEN KO cells exhibited constitutive AKT activation, as
assessed by phosphorylated serine-473 AKT protein cellular content
compared with their isogenic counterpart HCT116 PTENWT. There
was approximately two-fold increased p-AKT/total AKT ratio (Figure 1,
A and B). The presence or absence of serum within the growth medium
did not affect AKT activation status in both cell lines. Interestingly, stim-
ulation of the cells with 100 nM insulin induced AKT activation in
HCT116 PTENWTcells to levels similar to those in PTEN-deleted cells
at baseline. Insulin treatment also led to hyperactivation of AKT in
HCT116 PTEN KO, with the p-AKT/AKT ratio approximately two-
fold higher than that in the untreated PTEN KO cells, suggesting that
the PTEN-deleted cells display hyperactivated AKT (over the constitutive
activated AKT protein level) in response to growth factor stimulation.
PTEN Deletion/AKT Hyperactivation Is Not Associated with
a Growth Advantage
AKT activation has been reported to stimulate cell cycle progres-
sion, survival, and migration through phosphorylation of many phys-
iological substrates [17,21,22]. A study also reported that AKT
activation is required for both the cell survival and cell proliferation
phenotypes observed in PTEN-deleted embryonic stem cells [23].
Control of cell proliferation by PI3K/AKT is not, however, universal.
For example, activation of AKT in mammary epithelial carcinoma
cells was not associated with an increased tumor growth rate; further-
more, induction of constitutive AKT expression in nontumorigenic
human breast epithelial cells had minimal phenotypic consequences
and did not recapitulate the biochemical and growth characteristics
seen with somatic cell knock-in of PIK3CA gene [24–26]. We inves-
tigated the impact of PTEN deletion on cell proliferation in vitro
using a colorimetric assay and in vivo using [18F]FLT small-animal
PET imaging (Figures 2 and 3). Cell proliferation status was compa-
rable in unstimulated HCT116 PTEN KO and PTEN WT cells,
whereas on serum or insulin stimulation, PTEN-deleted cells exhib-
ited significant lower cell proliferation rates compared with the iso-
genic cell counterpart (approximately 15%-20% decrease; Figure 2).
This result is in line with studies reporting induction of cell growth
arrest and cellular senescence in PTEN-deleted/AKT-activated hu-
man prostate and colon carcinoma cells, through a p53-dependent
mechanism [27–29]. The in vivo tumor proliferation status of size-
matched HCT116 PTEN WT and HCT116 PTEN KO xenografts-
bearing mice was assessed by [18F]FLT-PET [9]. The significantly
lower [18F]FLT uptake in PTEN KO tumors compared with
PTEN WT tumors was seen on the tumor time-versus-radioactivity
curves and extracted semiquantitative values (approximately 20%
lower NUV60; Figure 3). Our in vitro and in vivo data, therefore,
indicated that PTEN deletion/AKT constitutive activation in the
HCT116 PTEN isogenic set is associated with a decreased cell pro-
liferation rate.
Figure 3. In vivo assessment of proliferation related to PTEN status using [18F]FLT PET imaging. Size-matched HCT116 PTENWT and KO
(bilateral implant) xenografts-bearing mice (n = 5) were subjected to 60 minutes of dynamic [18F]FLT PET imaging. (A) [18F]FLT PET
image of one representative mouse (arrows indicate the tumors). (B) The tumor time-versus-radioactivity curve normalized to heart
(TAC). (C) Semiquantitative imaging variables (NUV60, AUC, and FRT) extracted from the TAC. Data are mean ± SEM.
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PTEN Deletion/AKT Activation Is Not Associated with a
Glucose Metabolism Advantage
The PI3K pathway regulates glucose uptake and metabolism, and
tumors with high levels of PI3K signaling might require high rates of
glycolysis for their survival [1,30,31]. Moreover, it has been reported
that activation of the PI3K signaling pathway stimulates the switch
to aerobic glycolysis characteristic of cancer cells and that AKT acti-
vation renders cancer cells addicted to aerobic glycolysis for contin-
ued growth and survival [13]. We investigated the dynamics of
glucose metabolism of the isogenic HCT116 PTEN WT/KO cells
in vivo by [18F]FDG PET (Figure 4) and observed equivalent radio-
tracer uptake kinetics (NUV60 = 1.43 ± 0.23 and 1.39 ± 0.22, respec-
tively), indicating that PTEN deletion/AKT constitutive activation
was not associated with a glucose metabolic advantage. To demon-
strate that this was not due to activation context, that is, phosphatase
activity, we conducted a similar [18F]FDG PET imaging study in
isogenic HCT116 PIK3CA cells with the parental cells harboring a
wild-type PI3K (HCT116 PIK3CA WT) and the isogenic pair cells
expressing a constitutively activated PI3K (HCT116 PIK3CAMUT),
through targeted homologous integration, as previously described [19].
Similarly, there were no differences in [18F]FDG uptake in HCT116
xenografts derived from PIK3CA WT/MUT cells (Figure 5), support-
ing our aforementioned assertion that activation of the PI3K pathway
detected by p-AKT protein expression per se does not directly translate
into acquisition of an increased glucose metabolic phenotype.
[18F]FDG PET Imaging Detects Treatment-Induced PI3K
Inhibition Independent of PTEN Status
Many academic laboratories and pharmaceutical companies are
actively developing inhibitors that target PI3K and other key compo-
nents in the pathway [32]. LY294002 is a small molecule that com-
petitively and reversibly inhibits the ATP binding site of several
PI3Ks and has been widely used as a research tool to antagonize
PI3K signaling pathway [19,33]. LY294002 was potent in vitro in
the HCT116 PTEN isogenic cells arresting cell growth by approxi-
mately 40% independent of PTEN status or insulin stimulation (Fig-
ure 2). We, therefore, wondered if acute pharmacological inhibition
of PI3K by LY294002 (>3.5 hours) will alter glucose metabolism
in vivo. LY294002 treatment resulted in approximately 30% decrease
Figure 4. In vivo assessment of glucose metabolism related to PTEN status using [18F]FDG PET imaging. HCT116 PTEN WT and KO
(bilateral implant) xenografts-bearing mice were treated twice with 100 mg/kg LY294002 (3 hours 30 minutes before imaging, n = 4)
or corresponding vehicle (n = 6) and were subsequently subjected to 60 minutes of dynamic [18F]FDG PET imaging. (A) [18F]FDG PET
images of two representative mice (arrows indicate the tumors; b, bladder; k, kidneys). (B) The tumor time-versus-radioactivity curve
normalized to liver (TAC). (C, D) Semiquantitative imaging variables NUV60, AUC, and FRT extracted from the TAC. Data are mean ± SEM.
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in glucose metabolism of the isogenic HCT116 PTEN xenografts, as
detected by [18F]FDG PET imaging, independent of their PTEN
status (Figure 4). Subsequent ex vivo tumor tissues analysis con-
firmed that PI3K inhibition by LY294002 treatment had resulted
in the abrogation of AKT activation conferred by PTEN deletion
(Figure 6, A and B), most likely by reducing the PIP3 pool, leading
to the redistribution of GLUT-1 from the cell membrane to the cyto-
plasm, therefore compromising glucose transport and subsequent
metabolism (Figure 6C ).
To summarize, we showed that PTEN deletion compared with
WT PTEN in the HCT116 isogenic set of cells triggered constitutive
activation of AKT and growth factor–dependent AKT hyperactiva-
tion, which did not recapitulate the generally described PI3K path-
way oncogenic phenotype related to tumor growth and glucose
metabolism. Moreover, we showed that the direct inhibition of
PI3K resulted in the abrogation of AKT activation, relocation of
GLUT-1 to the cytoplasm, and subsequently decreased overall glucose
metabolism independent of the PTEN status and that, in our cellular
context, [18F]FDG PET imaging could be used as a biomarker of
response to anti-PI3K treatment.
Discussion
The loss of PTEN expression or the acquisition of activating PI3K
mutations occurs in many tumor types illustrating the importance of
the PI3K signaling pathway in cancer. We have shown that the absence
of PTEN expression on its own did not confer a proliferation or
metabolism advantage as assessed by [18F]FLT and [18F]FDG small-
animal PET imaging. Similarly, constitutive PI3K activation alone
(PIK3CAMUT) was not able to confer an increased glucose metabolic
phenotype. Although the contributions of PTEN and PIK3CA genetic
lesions in the PI3K oncogenic signaling pathway are widely reported,
the unique implication of each of these components in the overall
tumorigenic phenotype of cancer cells is not obvious and might be
subjected to a fine balance. A number of studies have found PTEN,
PIK3CA, and AKT mutations to be mutually exclusive in individual
tumors, suggesting that mutational activation of the PI3K pathway by
any one of these means is biologically equivalent [34–36]. These findings
are not, however, universal. There are, for instance, reports of a small
percentage of tumors with concurrent PTEN mutation/deletion and
PIK3CA mutation [37,38]; the frequency of such events may be higher
in particular tumor types and may reflect differences in tumor biology.
A recent study also indicates that, in contrast to PIK3CA mutations, the
AKT mutation does not confer growth factor independence and shows
distinct phenotypes arising from alterations in the same signaling path-
way [26]. AKT hyperactivation alone may, therefore, be insufficient to
recapitulate the entire PI3K oncogenic signaling phenotype of increased
survival, proliferation, and glucose metabolism. Although p-AKT protein
expression was assessed, the direct relationship between the magnitude of
protein expression and oncogenic phenotype is unclear. We speculate
that protein expression in WT cells is possibly already sufficient to acti-
vate glucose metabolism and proliferation. The unexpected reduced pro-
liferation in the HCT116 PTEN KO isogenic cells and xenografts may
be due to activation of senescence, analogous to recent report of increased
senescence after transgenic expression of activated AKT [39]. Similar to
PTEN loss, enforced AKT activation leads to senescence that is p53 de-
pendent [27] or p27 dependent [29]. Tumors may adapt to individual
PTEN or PIK3CA genetic changes by a variety of mechanisms. We have
only assessed the impact of PTEN on glucose metabolism and prolifer-
ation in this present study. The PI3K signaling pathway is also implicated
in various oncogenic processes including survival, invasion, and angio-
genesis, and further studies will be needed to fully understand the partic-
ular role of PTEN or PIK3CA genetic lesions in the overall tumorigenic
phenotype. This will ultimately be highly valuable in the development of
imaging biomarkers to fully characterize the efficacy of PI3K pathway
targeting therapeutics.
We demonstrated the utility of [18F]FDG PET imaging for the
assessment of acute PI3K inhibition and reduced AKT activation
Figure 5. In vivo assessment of metabolism related to PIK3CA sta-
tus using [18F]FDG PET imaging. HCT116 PIK3CA WT and MUT
(bilateral implant) xenografts-bearing mice (n = 5) were subjected
to 60 minutes of dynamic [18F]FDG PET imaging. (A) [18F]FDG PET
image of one representative mouse (arrows indicate the tumors;
b, bladder). (B) The tumor time-versus-radioactivity curve normal-
ized to liver (TAC). (C) Semiquantitative imaging variables NUV60
extracted from the TAC. Data are mean ± SEM.
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by LY294002 and showed that changes in tumor [18F]FDG kinetics
could be due at least in part to reduced membrane localization of
GLUT-1. Thus, [18F]FDG PET could represent a pharmacodynamic
biomarker of anti-PI3K pathway treatment. In this context, [18F]FDG
PET reports on the modulation of target activity rather that down-
stream changes in cell viability that is often associated with the use of
[18F]FDG PET [40–42]. We did not evaluate long-term/short-term
drug effects on [18F]FDG PET as LY294002 has poor pharmaco-
kinetics and is therefore unsuitable for chronic dosing [43–45]. Nota-
bly, the reduction in tumor glucose metabolism after LY294002
treatment occurred in both PTEN WT/KO xenografts, that is, drug-
induced changes in glucose metabolism were independent of the PTEN
expression status. This observation further supports our suggestion that
glucose metabolism is probably sufficiently activated in WT cells de-
spite the low activated AKT protein expression and, by extension, that
p-AKT protein expression per se may be an inappropriate marker of
cognate pathway effects on glucose metabolism.
We conclude that [18F]FDG PET is a suitable pharmacodynamic
biomarker of PI3K inhibition independent of PTEN status.
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